Compare Ginkgo Bioworks Holdings Inc (DNA) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Marqeta Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Marqeta Inc trades at $16.13 (market cap $1.70B). The key difference: Marqeta Inc is far larger — about 2.9× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| DNA | MQ | |
|---|---|---|
Market Cap | $590.53M | $1.70B |
Sector | Health | Technology |
52-Week High | $16.14 | $27.32 |
52-Week Low | $5.48 | $15.04 |
Enterprise Value | $627.78M | $999.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Marqeta (MQ) trades at $16.43, up 3.53% with a bullish technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with revenue growth from $507M in 2024 to $625M in 2025. A recent 1-for-4 reverse stock split took effect on July 1, 2026. Cash flow improved to a net positive $86M in 2025. Analyst consensus is a $19 price target with 32% buy ratings.
Outlook is cautiously optimistic given earnings volatility and high valuation multiples. Opportunities include European expansion and credit product growth, but risks involve thin net margins and potential fiduciary duty lawsuits. The stock's upside depends on sustained profitability and execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
